Testosterone intranasal - Acerus Pharmaceuticals Corporation

Drug Profile

Testosterone intranasal - Acerus Pharmaceuticals Corporation

Alternative Names: CompleoTRT™; MPP 10; Nasobol; Natesto; TBS-1

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mattern Pharmaceuticals
  • Developer Acerus Pharmaceuticals; Aytu BioScience; Hyundai Pharmaceutical
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone congener stimulants; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypogonadism

Most Recent Events

  • 23 Oct 2017 Intranasal testosterone licensed to Eu Hwa for marketing in Thailand, Malaysia/Brunei, Singapore, Vietnam, Philippines, Hong Kong/Macau and one other small South East Asian countries for the treatment of Hypogonadism
  • 14 Jun 2017 Testosterone intranasal gel licensed to Medac in Germany, United Kingdom, France, Italy, Czech Republic, Slovakia, Spain, Sweden, Finland, Denmark, Norway, Poland, Austria, Netherland and Belgium for commercialisation
  • 05 Jun 2017 Therios Healthcare acquires commercialisation license for testosterone nasal gel in Saudi Arabia, the United Arab Emirates and Egypt
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top